Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT05132257 |
| Other study ID # |
202001715A3 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
April 12, 2021 |
| Est. completion date |
March 31, 2024 |
Study information
| Verified date |
May 2023 |
| Source |
Chang Gung Memorial Hospital |
| Contact |
Wu WeiChi, M.D., PhD. |
| Phone |
886-3-3281200 |
| Email |
weichi666[@]gmail.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
Study Aim and Goals
1. Evaluate the correlation between genetic polymorphism and ROP development
2. To study the possibility if there are any specific genetic polymorphisms that lead to
poor outcome or recurrence of ROP after treatment.
Description:
Background:
The preterm neonate, especially the low birth weight infant, is at a greater risk to develop
disorders in multiple organ systems because of immaturity. Retinopathy of prematurity (ROP)
is a disorder of the developing retina of low birth weight preterm infants that has the
potential to lead to blindness. Although the pathogenesis and etiology of ROP remains
unclear, many causative factors have been proposed. Vascular endothelial growth factor (VEGF)
is an important regulator of angiogenesis in fetal life. In humans, polymorphisms in the VEGF
gene have been reportedly associated with proliferative diabetic retinopathy and age-related
degeneration. These retinal diseases might share the disease process of vasculopathy with
ROP. Besides risk factors specifically associated with preterm birth, the activation of
pro-inflammatory cytokines has been suggested to contribute to ROP development. Tumor
necrosis factor (TNF)-α is one of the major cytokines in inflammation. Its expression was
up-regulated in retinal neovascularization in animal models and proliferative eye diseases in
humans. Many researchers suggest that TNF-α may affect retinal angiogenesis and predispose
preterm infants for later development of ROP. Recent studies showed the possible correlation
between ROP and polymorphism in VEGF (-460 T/C, +936 C/T, -634 G/C, and -2578 C/A), or TNF-α
(-308 G/A). However, these studies focused on western populations. In our study, we will
analyze the relationships among severity, treatment outcomes, and genetic polymorphism
findings in ROP.
Study Aim and Goals
1. Evaluate the correlation between genetic polymorphism and ROP development
2. To study the possibility if there are any specific genetic polymorphisms that lead to
poor outcome or recurrence of ROP after treatment.
Study Design Participants: We plan to recruit the children born at Linkou and Taipei branches
of Chung Gung Memorial Hospital in 2009-2018, who are willing to undergo series of
ophthalmologic examinations.
Study period: April, 2021 to March, 2024. A prospective cohort study Inclusion criteria: All
children who were born at Linkou and Taipei branches of Chung Gung Memorial Hospital during
the period of 2009 to 2018.
Exclusion criteria: If the parents were not willing to participate the study, or the medical
records were not complete, or the follow period was less than 6 months.
Estimated patients' numbers: about 500 babies/3 years Methods: Participants will receive
series of ocular exams, including: cycloplegic refractions, strabismus exams, exams of
intraocular pressure, slit lamp exam, fundus exam, axial length measurement, etc. After the
parent's and the participant's agreement, we will have a blood test of 3 ml and undergo DNA
collection (Oragene-DNA; DNA-Genotek, Ottawa, Canada) by study personnel. We will analyze
around 10 SNPs from each of candidate genes in our study.
According to patients' previous records and images, subjects will be classified as cases and
controls. "Cases" will be infants with severe treatment-requiring ROP (defined as type-1 ROP
[zone I, any stage, with plus disease; zone I, stage 3, without plus disease; or zone II,
stage 2 or 3, with plus disease] or worse). "Controls" will be full-term babies without other
retinal disorder, infants with no ROP or with mild ROP less severe than type-1 ROP, who are
within the same birth weight group (e.g., <1000 grams or ≥1000 grams). After matching genetic
results and structural outcomes, we will analyze whether any specific genetic polymorphism
had higher presentations in treatment-requiring ROP patients. Also, secondary analysis will
focus on the difference between recurrent/poor outcome cases and other cases.
Statistical Analysis: Continuous variables will be analyzed with independent-t or paired-t
test. One-way ANOVA will be used to compare three or more groups. Ordinal variables will be
analyzed with Wilcoxon rank sum test (two independent samples) or Wilcoxon signed rank test
(tow paired samples). Categorical variables will be analyzed with Chi-square test or Fisher's
exact test. A multivariable logistic regression model will be constructed to assess the
association between myopia prevalence and all studied risk factors. P value <0.05 will be
considered statistically significant.
